Logo Image
Opinion|Videos|January 31, 2025

Switching Between BTK Inhibitors in CLL

Panelists discuss how decisions to switch between Bruton tyrosine kinase (BTK) inhibitors are driven by multiple factors including intolerable toxicities, development of resistance mutations, disease progression, drug interactions, and patient preferences, with pirtobrutinib emerging as a particularly valuable option for patients with BTK C481 mutations or those who have exhausted other BTK inhibitor (BTKi) options.

Episodes in this series

Video content above is prompted by the following:

  • What factors typically drive decisions to switch between BTK inhibitors: managing toxicity, addressing disease progression, or other considerations?
  • How do these factors influence your decision on which therapy to switch to, either within the BTKi class or outside of it? Where does pirtobrutinib fit into this decision?

Related Content